Chicken Epinephrine/Adrenaline ELISA Kit

Name: Chicken Epinephrine/Adrenaline ELISA Kit
SKU: DEIA-BJ2932
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, plasma, cell culture supernatants, body fluid and tissue homogenate

Species Reactivity

Chicken

Detection Method

Competitive ELISA

Intended Use

Chicken Epinephrine/Adrenaline ELISA Kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of the Epinephrine/Adrenaline. This ELISA kit is for research use only, not for therapeutic or diagnostic applications.

Contents of Kit

1. MICROTITER PLATE: 96 wells
2. ENZYME CONJUGATE: 6.0 mL or 10 ml
3. STANDARD A-F: 1 vial each
4. SUBSTRATE A: 6 mL
5. SUBSTRATE B: 6 mL
6. STOP SOLUTION: 6 mL
7. WASH SOLUTION (100 x): 10 mL
8. BALANCE SOLUTION: 3 mL

Storage

All components of this kit are stable at 2-8°C until the kit's expiration date.

Detection Range

250-5000 pg/mL

Sensitivity

1.0 pg/mL

Citations

Have you cited DEIA-BJ2932 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Epinephrine in anaphylaxis: too little, too late

CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY

Authors: Lieberman, Jay Adam; Wang, Julie

Abstract

Purpose of review Epinephrine is the agreed-upon first line treatment for anaphylaxis, yet it continues to be underused by patients/caregivers and providers alike. Recent findings There are unfortunately limited data on how epinephrine can best be utilized in anaphylaxis, which hinders how best to inform patients and providers. Studies reporting underuse suggest various barriers and themes on why this may happen. Continued education of patients, caregivers, and providers is needed; however, is not likely to be enough to close the gap. Thus, novel studies on how to increase use; increase availability in a cost-effective manner; and newer, effective delivery routes are still needed.

Efficacy and safety of corticosteroid therapy in patients with cardiac arrest: a systematic review of randomised controlled trials

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Authors: Li, Yajie; Zhang, Jun; Cai, Nan; He, Fei

Abstract

Purposes The role of corticosteroid therapy in patients with cardiac arrest (CA) is uncertain. We aimed to evaluate the efficacy and safety of corticosteroid therapy in CA patients. Methods Randomised controlled trials were identified using PubMed, EMBASE, Cochrane Central Register of Controlled Trials, the Chinese National Knowledge Infrastructure and the Chinese Biomedical Literature Database. The primary outcome was overall survival. Secondary outcomes were positive neurological status and probability of sustained restoration of spontaneous circulation (ROSC). Complications were infection and bleeding. Given the significant heterogeneity across previous studies, combining the data using meta-analysis was deemed not appropriate. Results Five studies (551 patients) met the criteria. Two studies of co-intervention therapy (corticosteroid, vasopressin and epinephrine protocol) found that this approach could benefit in-hospital CA patient survival rates at hospital discharge, improve neurological function at hospital discharge and yield sustained ROSC rate. However, further two studies failed to demonstrate that corticosteroid therapy alone could improve survival and neurological outcomes among CA patients. Additionally, corticosteroid therapy did not increase the risk of infection and bleeding. Conclusions Due to the inherent limitations of the studies in this review, we have not been able to reach definitive conclusions. Larger-scale and better-designed studies are therefore recommended, to further evaluate the potential and rational use of corticosteroid therapy in CA patients.